New targets for therapy in Parkinson's disease: Pathogenesis and pathophysiology

Functional Neurology

Volumn 15, Issue 2, 2000, Pages 67-80

  Greenamyre, John Timothy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Basal ganglia; Glutamate; Mitochondria; Neuroprotection; Rotenone

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA SYNUCLEIN; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; ANTIOXIDANT; APOMORPHINE; CREATINE; DNA; DOPAMINE; DOPAMINE TRANSPORTER; GLUTAMIC ACID; GLUTATHIONE; KAINIC ACID RECEPTOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID; NAXAGOLIDE; ROTENONE; SCAVENGER; TYROSINE 3 MONOOXYGENASE; UBIQUITIN; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

APOPTOSIS; CONFERENCE PAPER; DRUG INHIBITION; DRUG POTENTIATION; HUMAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; TREATMENT OUTCOME; ANIMAL; ANIMAL MODEL; ARTICLE; AWARDS AND PRIZES; BINDING COMPETITION; BRAIN; CORPUS STRIATUM; DOWN REGULATION; DRUG EFFECT; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; PUTAMEN; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; AWARDS AND PRIZES; BINDING, COMPETITIVE; BRAIN; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOWN-REGULATION; HUMANS; MODELS, ANIMAL; NEURONS; PARKINSON DISEASE; PUTAMEN; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTANTIA NIGRA;

EID: 0034169661     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047
2. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608
3. Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991;14:153-197
4. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993;52:183-191
5. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840
6. Sian J, Dexter DT, Lees AJ et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355
7. Dexter DT, Holley AE, Flitter WD et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994; 9:92-97
8. Alam ZI, Jenner A, Daniel SE et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69:1196-1203
9. Tanner CM, Ottman R, Goldman SM et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341-346
10. Bernheimer H, Hornykiewicz O. Decreased homovanillic acid concentration in the brain in parkinsonian subjects as an expression of a disorder of central dopamine metabolism. Klin Wochenschr 1965;43:711-715
11. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998;51 (Suppl. 2):S2-9
12. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998;50:1346-1350
13. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 1993;43: 1693-1697
14. Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson's disease. Neurology 1993;43:1150-1158
15. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827
16. Schapira AH, Mann VM, Cooper JM et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990;55:2142-2145
17. Parker WD, Jr., Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989;26:719-723
18. Bindoff LA, Birch-Machin MA, Cartlidge NE, Parker WD, Jr., Turnbull DM. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 1991;104:203-208
19. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992;4:27-34
20. Haas RH, Nasirian F, Nakano K et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37: 714-722
21. Swerdlow RH, Parks JK, Miller SW et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996;40:663-671
22. Schapira AH, Gu M, Taanman JW et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 1998;44:S89-98.
23. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochem Biophys Acta 1998;1364:222-235
24. Soloway SB. Naturally occurring insecticides. Environ Health Perspect 1976;14:109-117
25. Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 1994;36:882-888
26. Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1998;783:109-114
27. Matthews RT, Yang L, Jenkins BG et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 1998;18:156-163
28. Matthews RT, Ferrante RJ, Klivenyi P et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999; 157:142-149
29. Zeevalk GD, Bernard LP, Albers DS, Mirochnitchenko O, Nicklas WJ, Sonsalla PK. Energy stress-induced dopamine loss in glutathione peroxidase-overexpressing transgenic mice and in glutathione-depleted mesencephalic cultures. J Neurochem 1997;68:426-429
30. Gash DM, Zhang Z, Ovadia A et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380:252-255
31. Barkats M, Bilang-Bleuel A, Buc-Caron MH et al. Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases. Prog Neurobiol 1998;55: 333-341
32. Greenamyre JT. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm General Section 1993;91:255-269
33. Starr MS. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 1995; 19:264-293
34. Wichmann T, DeLong MR. Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 1996;6:751-758
35. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375
36. Calabresi P, Mercuri NB, Sancesario G, Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 1993; 116:433-452
37. Dingledine R, Boland LM, Chamberlin NL et al. Amino acid receptors and uptake systems in the mammalian central nervous system. Crit Rev Neurobiol 1988;4:1-96
38. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999;51:7-61
39. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997;37: 205-237
40. Borges K, Dingledine R. AMPA receptors: molecular and functional diversity. Prog Brain Res 1998;116:153-170
41. Sheardown MJ, Nielsen EO, Hansen AJ, Jacobsen P, Honore T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990;247:571-574
42. Donevan SD, Rogawski MA. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 1993;10:51-59
43. Porter RH, Greene JG, Higgins DS, Jr., Greenamyre JT. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J Neurosci 1994;14:7192-7199
44. Blandini F, Garcia-Osuna M, Greenamyre JT. Subthalamic ablation reverses changes in basal ganglia oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion in rats. Eur J Neurosci 1997;9:1407-1413
45. Blandini F, Porter RH, Greenamyre JT. Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion. Neurosci Lett 1995; 186:99-102
46. Blandini F, Greenamyre JT. Effect of subthalamic nucleus lesion on mitochondrial enzyme activity in rat basal ganglia. Brain Res 1995;669:59-66
47. Betarbet R, Porter RH, Greenamyre JT. GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation. J Neurochem 2000;74:1166-1174
48. Bernard V, Gardiol A, Faucheux B, Bloch B, Agid Y, Hirsch EC. Expression of glutamate receptors in the human and rat basal ganglia: effect of the dopaminergic denervation on AMPA receptor gene expression in the striatopallidal complex in Parkinson's disease and rat with 6-OHDA lesion. J Comp Neurol 1996;368:553-568
49. Tremblay M, Salin P, Soghomonian JJ. Effect of 6-OHDA lesions on striatal mRNA levels encoding for glutamate receptor subunits. Neuroreport 1995;6:2225-2229
50. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-1438
51. Klockgether T, Turski L, Honore T et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991;30:717-723
52. Fenu S, Carta A, Morelli M. Modulation of dopamine D1-mediated turning behavior and striatal c-fos expression by the substantia nigra. Synapse 1995;19:233-240
53. Vila M, Marin C, Ruberg M et al. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia. J Neurochem 1999;73:344-352
54. Stauch Slusher B, Rissolo KC, Anzilotti KF, Jr., Jackson PF. Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats. J Neural Transm Park Dis Dement Sect 1995;9:145-149
55. Loschmann PA, Wullner U, Heneka MT et al. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Synapse 1997;26:381-391
56. Loschmann PA, Lange KW, Kunow M et al. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1991;3:203-213
57. Luquin MR, Obeso JA, Laguna J, Guillen J, Martinez-Lage JM. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur J Pharmacol 1993;235:297-300
58. Kurlan R. Practical therapy of Parkinson's disease. Semin Neurol 1987;7:160-166
59. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998;13:871-876
60. Crossman AR. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987;21:1-40
61. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996;39:574-578
62. Greenamyre JT. Pharmacological pallidotomy with glutamate antagonists? Ann Neurol 1996;39:557-558